

Robust Q1, growth story intact

Sales grew 24% YoY driven by higher share of domestic markets aided by COVID (lower demand of hospital led surgery products was offset by respiratory and diagnostics kits). Higher polymer prices continued in Q1 as well but ability to pass prices to customers aided gross margins at 66% (flat YoY, up 100bps QoQ). Higher freight charges restricted EBITDA margins at 26%. PAT at Rs376mn was up 41% YoY, 30% higher vs our estimate of Rs282mn, aided by higher net interest income. In Q1, product mix changed resulting into 62% of revenue from exports and 38% from domestic markets. Management reiterated its guidance of 17-18% revenue growth with sustained EBITDA margin for FY22E. Proceeds from QIP will be utilized to enhance its offerings in the renal care segment under the PLI scheme. Company is on track to achieve its guidance of being debt free by FY23E.

Key triggers: 1) PLI scheme for renal care, capex guided of Rs1.5bn over next 2 years with asset turn of 1.2-1.5x, 2) Renal guided to become 7-8x in next 5 years (Rs320mn as on FY21), 3) New launches in respiratory, syringes (for vaccine market), diagnostic kits to contribute meaningfully over the next 2-3 years, 4) Looking at inorganic opportunities, 5) Entry into newer markets like US (expect USFDA approval and launches from 2HFY22). It has also taken board approval to set up an office in the UK and is in advanced discussion with 3-4 large customers for direct distribution.

Outlook and Valuation: Polymed has grown at 15% and 25% CAGR in revenue and PAT respectively during FY17-21 with margins improving by 700 bps to 27.3% in FY21. Further, it has improved its CFO/EBITDA from 60% in FY18 to 82% in FY20. We believe PLI scheme and medical device regulation will be a game changer for organized players like Polymed in an unorganized fragmented market. Assuming overall capex of Rs2.5bn for the PLI scheme and asset turn 1.4x, our back of the envelope calculations suggest, revenue potential of Rs3.5bn over FY24-27E. Further assuming the margins at 28%, we believe PLI optionality to be at Rs215 (20x EV/EBITDA). We pencil 20% earnings CAGR over FY21-23E and value the base business at 45x FY23E earnings. **Maintain Buy.**

Q1FY22 Result (Rs Mn)

Particulars	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)
Revenue	2,119	1,704	24.4	2,130	(0.5)
Total Expense	1,566	1,245	25.8	1,588	(1.4)
EBITDA	553	459	20.7	542	2.1
Depreciation	129	110	17.2	125	2.6
EBIT	425	349	21.8	416	2.0
Other Income	103	35	196.4	67	54.1
Interest	32	28	14.5	(18)	(274.6)
EBT	495	355	39.4	501	(1.2)
Tax	126	95	32.1	130	(2.9)
RPAT	376	267	40.7	388	(3.2)
APAT	376	267	40.7	388	(3.2)
			(bps)		(bps)
Gross Margin (%)	66.1	65.7	35	64.6	146
EBITDA Margin (%)	26.1	26.9	(80)	25.4	66
NPM (%)	17.7	15.7	206	18.2	(50)
Tax Rate (%)	25.4	26.8	(139)	25.9	(43)
EBIT Margin (%)	20.0	20.5	(43)	19.6	48

CMP	Rs 982
Target / Upside	Rs 1,136 / 16%
NIFTY	15,763

Scrip Details

Equity / FV	Rs 479mn / Rs 5
Market Cap	Rs 94bn
	USD 1bn
52-week High/Low	Rs 1,165/ 365
Avg. Volume (no)	187,692
Bloom Code	PLM IN

Price Performance	1M	3M	12M
Absolute (%)	(3)	(1)	149
Rel to NIFTY (%)	(4)	(9)	107

Shareholding Pattern

	Dec'20	Mar'21	Jun'21
Promoters	48.8	44.9	44.9
MF/Banks/FIs	0.3	2.5	2.5
FII	3.8	12.6	12.6
Public / Others	47.2	40.0	40.0

Valuation (x)

	FY21E	FY22E	FY23E
P/E	69.1	56.2	48.5
EV/EBITDA	42.6	36.4	30.6
ROE (%)	19.4	16.5	17.2
RoACE (%)	16.4	14.8	15.6

Estimates (Rs mn)

	FY21E	FY22E	FY23E
Revenue	7,865	9,437	10,919
EBITDA	2,144	2,515	2,978
PAT	1,361	1,674	1,942
EPS (Rs.)	14.2	17.5	20.3

VP - Research: Sapna Jhawar

Tel: +9122 40969724

E-mail: sapnaj@dolatcapital.com

Associate: Zain Gulam Hussain

Tel: +9122 40969725

E-mail: zain@dolatcapital.com

Exhibit 1: Revenue Break-up (Rs mn)

Particulars	FY21	FY20	% YoY
India	2,186	1,868	17.0
Export	5,679	4,824	17.7
Total Sales	7,865	6,693	17.5

Source: DART, Company

Exhibit 2: Segment break-up (Rs mn)

Particulars	FY21	FY20	% YoY
Infusion therapy	5,584	4,685	19.2
Blood Transfusion	708	602	17.5
Renal	314.6	267.7	17.5
Respiratory	236	268	-11.9
Others	1,022	870	17.5
Total Sales	7,865	6,693	17.5

Source: DART, Company

Concall takeaways

- **Guidance:** Revenue growth of 17-18% and EBITDA margins to be sustained at 25-26% despite higher raw material prices. Indian market is expected to grow at 25-30% and exports at ~12%. The guidance does not include contribution from new launches. Long term EBITDA guidance reiterated at 30%. Capex guided at Rs2.5bn for next 18 months. Of this, Rs1.5bn will be utilized towards PLI scheme. Apart from renal category, company will focus on infusion and diagnostics business (planned capex of Rs1bn).
- **New launches in FY22E:** Amongst other products, Polymed plans to launch nebulizer machine, syringes. It has already launched RT-PCR kit, COVID antigen kit, single use dialyzer and Y connectors (used in oxygen cylinders) in Q1 and the initial response for the product has been encouraging. Company believes that higher volumes in these products will compensate for their low value thereby sustaining EBITDA margins.
- **PLI Update:** Management remain upbeat on the opportunities in renal segment (currently 85-90% imported). In FY21, Renal contributed Rs360mn, 5% of sales and management guided this to grow 7-8x over the next 5 years. Besides, the company also plans to apply for PLI 2 scheme under the diagnostic products scheme.
- **COVID:** Q1FY22 has seen higher contribution from domestic market aided by COVID. Higher demand of products in respiratory segment (nasal tubes, connectors, oxygen masks) and diagnostics (blood collection tubes, rapid test kits) aided growth. It also helped company made inroads with major diagnostic chains in India along with other key hospitals. Management mentioned that it had ramped up capacity by 2-3x for these 2 segments given the higher demand. Besides, it does see increased demand for syringes used for vaccines and diagnostic kits, manufacturing for which is on stream.
- **Higher costs:** Apart from high raw material prices (up by ~70-80% YoY), Polymed's margins were impacted due to higher logistics and freight costs in Q1 as well. While large part of this cost is passed through, some cost increase has impacted margins.
- **US launch:** Company expects USFDA approval in next 1-2 quarters and product launch to start from 2HFY22E onwards. Revenue contribution should be largely seen from FY23E onwards. Company is in process of hiring sales force (3-4 people) in the US and plans to set up an R&D center in North Carolina. Total investment for this is expected to be in the range of US\$2-3mn.
- **India:** All the new product launches would initially be launched in India and then in the exports market. Its distributor strength stands at 223 and sales and marketing team at 200. In terms of customer network, Polymed has added multiple hospitals, diagnostic chains.

Profit and Loss Account

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Revenue	6,872	7,865	9,437	10,919
Total Expense	5,233	5,721	6,922	7,941
COGS	2,170	2,619	3,021	3,468
Employees Cost	1,388	1,418	1,670	1,912
Other expenses	1,675	1,685	2,232	2,561
EBIDTA	1,640	2,144	2,515	2,978
Depreciation	405	475	544	612
EBIT	1,234	1,668	1,971	2,366
Interest	183	85	53	53
Other Income	185	184	265	222
Exc. / E.O. items	0	0	0	0
EBT	1,236	1,767	2,183	2,535
Tax	298	439	546	634
RPAT	959	1,361	1,674	1,942
Minority Interest	0	0	0	0
Profit/Loss share of associates	21	33	36	40
APAT	959	1,361	1,674	1,942

Balance Sheet

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Sources of Funds				
Equity Capital	441	479	479	479
Minority Interest	0	0	0	0
Reserves & Surplus	3,907	9,176	10,209	11,450
Net Worth	4,348	9,656	10,689	11,930
Total Debt	1,686	1,034	984	974
Net Deferred Tax Liability	252	239	250	262
Total Capital Employed	6,287	10,929	11,923	13,166

Applications of Funds

Net Block	3,278	3,905	4,805	5,155
CWIP	598	520	603	657
Investments	619	755	694	694
Current Assets, Loans & Advances	3,178	7,058	6,632	7,546
Inventories	1,121	1,265	1,227	1,377
Receivables	1,271	1,565	1,396	1,615
Cash and Bank Balances	254	296	48	570
Loans and Advances	1	3	4	5
Other Current Assets	372	479	508	529

Less: Current Liabilities & Provisions	1,386	1,308	809	886
Payables	664	645	657	711
Other Current Liabilities	723	663	152	174

sub total

Net Current Assets	1,791	5,750	5,823	6,660
Total Assets	6,287	10,929	11,923	13,166

E – Estimates

Important Ratios

Particulars	FY20A	FY21E	FY22E	FY23E
(A) Margins (%)				
Gross Profit Margin	68.4	66.7	68.0	68.2
EBIDTA Margin	23.9	27.3	26.7	27.3
EBIT Margin	18.0	21.2	20.9	21.7
Tax rate	24.2	24.9	25.0	25.0
Net Profit Margin	14.0	17.3	17.7	17.8
(B) As Percentage of Net Sales (%)				
COGS	31.6	33.3	32.0	31.8
Employee	20.2	18.0	17.7	17.5
Other	24.4	21.4	23.6	23.5
(C) Measure of Financial Status				
Gross Debt / Equity	0.4	0.1	0.1	0.1
Interest Coverage	6.7	19.6	36.9	44.7
Inventory days	60	59	47	46
Debtors days	68	73	54	54
Average Cost of Debt	12.0	6.3	5.3	5.4
Payable days	35	30	25	24
Working Capital days	95	267	225	223
FA T/O	2.1	2.0	2.0	2.1
(D) Measures of Investment				
AEPS (Rs)	10.0	14.2	17.5	20.3
CEPS (Rs)	14.2	19.2	23.1	26.6
DPS (Rs)	2.2	3.6	4.1	4.8
Dividend Payout (%)	22.2	25.4	23.7	23.5
BVPS (Rs)	45.4	100.7	111.5	124.4
RoANW (%)	23.5	19.4	16.5	17.2
RoACE (%)	19.1	16.4	14.8	15.6
RoAIC (%)	22.5	20.0	17.5	19.3
(E) Valuation Ratios				
CMP (Rs)	982	982	982	982
P/E	98.2	69.1	56.2	48.5
Mcap (Rs Mn)	94,116	94,116	94,116	94,116
MCap/ Sales	13.7	12.0	10.0	8.6
EV	95,390	91,405	91,603	91,070
EV/Sales	13.9	11.6	9.7	8.3
EV/EBITDA	58.2	42.6	36.4	30.6
P/BV	21.6	9.7	8.8	7.9
Dividend Yield (%)	0.2	0.4	0.4	0.5
(F) Growth Rate (%)				
Revenue	12.5	14.4	20.0	15.7
EBITDA	26.7	30.7	17.3	18.4
EBIT	33.9	35.2	18.2	20.0
PBT	25.2	43.0	23.5	16.1
APAT	46.6	42.0	23.0	16.0
EPS	46.6	42.0	23.0	16.0

Cash Flow

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
CFO	1,342	1,003	2,321	2,176
CFI	(156)	(3,290)	1	1
CFF	(153)	3,434	(1,233)	(715)
FCFF	(140)	(3,392)	985	1,238
Opening Cash	546	254	296	48
Closing Cash	254	296	48	570


E – Estimates

DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Dec-20	Buy	620	503
Jan-21	Buy	620	515
Feb-21	Buy	620	592
May-21	Accumulate	1,136	1,046

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
--------------------	--------------------------	--------------------------------	------------------------

Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
--------------------------	-------------------------	------------------------------	------------------------

CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Ashwani Kandoi	AVP - Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Dinesh Mehta	Co- Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

Dolat Capital Market Private Limited.

Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013

Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: "This Report is considered independent third-party research and was prepared by Dolat Capital Market Private Limited, with headquarters in India. The distribution of this Research is provided pursuant to the exemption under Rule 15a-6(a) (2) and is only intended for an audience of Major U.S. Institutional Investors (MUSIIs) as defined by Rule 15a-6(b)(4). This research is not a product of StoneX Financial Inc. Dolat Capital Market Private Limited has sole control over the contents of this research report. StoneX Financial Inc. does not exercise any control over the contents of, or the views expressed in, any research reports prepared by Dolat Capital Market Private Limited and under Rule 15a-6(a) (3), any U.S. recipient of this research report wishing to affect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through StoneX Financial Inc. Please contact Paul Karrlsson-Willis at +1 (407) 741-5310 or email Paul.Karrlsson-Willis@stonex.com and/or Igor Chernomorskiy at +1 (212)379-5463 or email Igor.Chernomorskiy@stonex.com. Under no circumstances should any U.S. recipient of this research report effect any transaction to buy or sell securities or related financial instruments through the Dolat Capital Market Private Limited."



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE – INZ000274132, NSE - INZ000274132, Research: INH0000000685

Registered office: Unit no PO6-02A - PO6-02D, Tower A, WTC, Block 51, Zone-5, Road 5E, Gift City, Gandhinagar, Gujarat – 382355

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com
